Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL97332 | 1.00 | SIGMAR1 (0.52) | SIGMAR1MAPTRXFP1IDO1FFAR1 | |
| SCHEMBL2517 | 0.98 | SIGMAR1 (0.48) | SIGMAR1MAPTRXFP1IDO1FFAR1 | |
| SCHEMBL5547690 | 0.95 | TDP1 (0.49) | SIGMAR1MAPTRXFP1IDO1FFAR1 | |
| SCHEMBL2961385 | 0.95 | TDP1 (0.49) | SIGMAR1MAPTRXFP1IDO1FFAR1 | |
| SCHEMBL96791 | 0.95 | TDP1 (0.49) | SIGMAR1MAPTRXFP1IDO1FFAR1 | |
| SCHEMBL5546766 | 0.95 | TDP1 (0.49) | SIGMAR1MAPTRXFP1IDO1FFAR1 | |
| SCHEMBL5537354 | 0.95 | TDP1 (0.49) | SIGMAR1MAPTRXFP1IDO1FFAR1 | |
| SCHEMBL5544777 | 0.95 | TDP1 (0.49) | SIGMAR1MAPTRXFP1IDO1FFAR1 | |
| SCHEMBL5545719 | 0.95 | TDP1 (0.49) | SIGMAR1MAPTRXFP1IDO1FFAR1 | |
| SCHEMBL5543105 | 0.95 | TDP1 (0.49) | SIGMAR1MAPTRXFP1IDO1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024075815-A1 | 8-HYDROXYQUINOLINE COMPOUND AND USE THEREOF | 国立大学法人大阪大学 | 2024-04-11 | — | — | WO | disclosed |
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| CN-105408325-B | cyanotriazole compounds | 大塚制药株式会社 | 2019-10-22 | — | — | CN | disclosed |
| US-9603833-B2 | Benzene or thiophene derivative and use thereof as VAP-1 inhibitor | R-TECH UENO, LTD. (JP) | 2017-03-28 | — | — | US | disclosed |
| WO-2016194390-A1 | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF CANCER | R-TECH UENO, LTD. (JP) | 2016-12-08 | — | — | WO | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| EP-3022199-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2016-05-25 | — | — | EP | disclosed |
| CN-105408325-A | Cyanotriazole compounds | OTSUKA PHARMA CO LTD | 2016-03-16 | — | — | CN | disclosed |
| EP-2650287-B9 | Thiazole Derivative and use thereof as VAP-1 Inhibitor | R TECH UENO LTD (JP) | 2015-08-05 | — | — | EP | disclosed |
| EP-0236140-A2 | Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-09-09 | — | — | EP | disclosed |
| US-4539151-A | Benzothiazepine derivatives and their method of preparation | MITSUI TOATSU CHEMICALS, INC. (JP) | 1985-09-03 | — | — | US | disclosed |
| US-4539150-A | HYPOTENSIVE AGENTS, SULFIDING, CYCLIZATION | MITSUI TOATSU CHEMICALS, INC. (JP) | 1985-09-03 | — | — | US | disclosed |
| US-4420624-A | ANTIBIOTICS | THE UPJOHN COMPANY (US) | 1983-12-13 | — | — | US | disclosed |
| US-4361701-A | SPECTINOMYCIN ANTIBIOTICS | THE UPJOHN COMPANY (US) | 1982-11-30 | — | — | US | disclosed |
| US-4351771-A | Spectinomycin analogs and methods for the preparation thereof | THE UPJOHN COMPANY (US) | 1982-09-28 | — | — | US | disclosed |
| US-4345086-A | ETHERIFICATION, CYCLIZATION, SULFIDING | THE UPJOHN COMPANY (US) | 1982-08-17 | — | — | US | disclosed |
| US-4344882-A | Intermediate compounds in the preparation of spectinomycin | THE UPJOHN COMPANY (US) | 1982-08-17 | — | — | US | disclosed |
| US-4337347-A | ANTIBIOTICS | THE UPJOHN COMPANY (US) | 1982-06-29 | — | — | US | disclosed |
| US-4282152-A | Intermediates for preparing spectinomycin and analogs thereof | THE UPJOHN COMPANY (US) | 1981-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | SIGMAR1 4091/4885MAPT 2196/4885RXFP1 2555/4885 |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | CS, PC, ACAT1 | SIGMAR1 4091/4885MAPT 2196/4885RXFP1 2555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.